{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-013659","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.959133+00:00","generated_at":"2026-05-15T06:58:36.637664+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Insmed's brensocatib fails Phase 2b HS study; program discontinued","bullets":["Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.","Secondary efficacy endpoints also not met; Insmed halts HS development of brensocatib.","Safety consistent with prior studies; no new signals; 40mg dose well tolerated.","Study enrolled 214 patients at 72 sites; 16-week placebo-controlled phase completed.","Topline results will be presented at a future medical congress."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-013659","json":"https://secwatch.observer/filing/0001140361-26-013659.json","markdown":"https://secwatch.observer/filing/0001140361-26-013659.md","text":"https://secwatch.observer/filing/0001140361-26-013659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/0001140361-26-013659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/ef20070042_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:58:36.637664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}